MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in airtight containers. Protect from light and maximum 8 days in MCA.

Provenance

This compatibility recommendation is derived from Natrilix SR 1.5mg tablets (Servier Laboratories Ltd).

Stability Notes

Protect from light and moisture. Store in airtight containers.

Provenance

This compatibility recommendation is derived from generic cetirizine 10mg tablets.

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Benadryl Allergy Relief 8mg capsules (McNeil Products Ltd).

Stability Notes

Store in airtight containers, protect from light. Store in tight or well-closed containers.

Provenance

This compatibility recommendation is derived from Piriton 4mg tablets (GlaxoSmithKline Consumer Healthcare UK Ltd).

Stability Notes

Protect from excessive moisture.

Provenance

This compatibility recommendation is derived from Fexofenadine 120mg tablets (Dr Reddy's Laboratories (UK) Ltd) and Telfast 120mg tablets (Sanofi).

Stability Notes

Protect from excessive moisture.

Provenance

This compatibility recommendation is derived from Fexofenadine 180mg tablets (Dr Reddy's Laboratories (UK) Ltd) and Telfast 180mg tablets (Sanofi).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.